Variables
|
DFS (n = 63)
|
NDFS (n = 30)
|
Healthy (n = 30)
|
pa
|
---|
Sex M/F
|
45/18
|
11/19
|
14/16
|
0.003
|
Hypertension (n/%)
|
58/92
|
24/80
|
14/46
|
< 0.0005
|
Cardiovascular events (n/%)
|
24/38
|
12/40
|
20/66
|
0.028
|
Stroke (n/%)
|
13/20
|
4/13
|
3/10
|
0.380
|
Dyslipidemia (n/%)
|
45/71
|
18/60
|
24/80
|
0.231
|
Smoker (n/%)
|
23/36
|
10/33
|
25/83
|
< 0.0005
|
Beta blocker (n/%)
|
20/31
|
13/43
|
12/40
|
0.503
|
Calcium channel blocker (n/%)
|
27/42
|
13/43
|
12/40
|
0.958
|
ACE inhibitor or ARBs (n/%)
|
26/41
|
13/43
|
12/40
|
0.965
|
Statin (n/%)
|
47/74
|
20/66
|
25/83
|
0.331
|
Antiplatelet (n/%)
|
28/44
|
10/33
|
13/43
|
0.580
|
GLP-1 agonist or DPP4 inhibitors (n/%)
|
1/1
|
5/16
|
0/0
|
0.002
|
Sulfonylurea (n/%)
|
1/1
|
11/36
|
0/0
|
< 0.0005
|
Metformin (n/%)
|
10/15
|
16/53
|
0/0
|
< 0.0005
|
Insulin (n/%)
|
63/100
|
6/20
|
0/0
|
< 0.0005
|
- DFS, diabetes foot syndrome; ARBs, Angiotensin II receptor blockers
- GLP-1: Glucagon-like peptide-1 receptor; DPP4 inhibitors, Inhibitors of dipeptidyl peptidase 4
- ap, intergroup differences among patient groups (chi-square test or Fisher’s test, as needed)